← Russell 3000 cross-section

VRDN Viridian Therapeutics, Inc.\DE

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$2.7bn
Revenue TTM
$71m
Net income TTM
$-387m
Free cash flow
$-335m
Composite score
Sector rank
#1460

Valuation

P / E
EV / EBITDA
EV / sales
26.7
FCF yield
-12.32%
Earnings yield vs 10-yr
-18.96pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-544.1%
EBITDA margin
-569.0%
ROE
-58.5%
ROIC
Revenue growth
23,220.3%

Insider activity, last 90 days

Net open-market
$-0.35m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In September 2025, we announced that REVEAL-1 and REVEAL-2 completed enrollment, enrolling 132 and 204 patients, respectively, each exceeding its target enrollments of 117 and 195 patients, respectively, due to demand. 67% of REVEAL-1 patients were enrolled from the U.S., and 56% of REVEAL-2 patients were enrolled from the U.S. Financial Operations Overview Revenue Our revenue has historically consisted primarily of up-front payments for licenses, milestone payments, and payments for other research and development services earned under license and collaboration agreements as well as for amounts earned under certain grants we have been awarded. …Viridian Therapeutics, Inc.\DE, 10-K, period ended 2025-12-31, filed 2026-02-26

Read the full passage →